Trivalent split Inf — Competitive Intelligence Brief

Trivalent split Inf (Trivalent split Inf) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated influenza vaccine. Area: Immunology / Infectious Disease.

marketed Inactivated influenza vaccine Immunology / Infectious Disease Biologic

Target snapshot

Trivalent split Inf (Trivalent split Inf) — National Institute of Allergy and Infectious Diseases (NIAID). Trivalent split influenza vaccine stimulates the immune system to produce antibodies against three strains of influenza virus.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Trivalent split Inf TARGET	Trivalent split Inf	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	Inactivated influenza vaccine
Vaxigrip®	Vaxigrip®	National University Hospital, Singapore	marketed	Inactivated influenza vaccine
ccIIV4	ccIIV4	Vanderbilt University Medical Center	marketed	Inactivated influenza vaccine
Prepandrix™	Prepandrix™	GlaxoSmithKline	marketed	Inactivated influenza vaccine	H5N1 influenza virus surface antigens (hemagglutinin and neuraminidase)
High-Dose Influenza Vaccine	High-Dose Influenza Vaccine	Saad Jamshed MD	marketed	Inactivated influenza vaccine
High Dose Trivalent Influenza Vaccine	High Dose Trivalent Influenza Vaccine	Brigham and Women's Hospital	marketed	Inactivated influenza vaccine
Vaxigrip Tetra Sanofi Pasteur Europe	Vaxigrip Tetra Sanofi Pasteur Europe	Aarhus University Hospital	marketed	Inactivated influenza vaccine (quadrivalent)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated influenza vaccine class)

1. GlaxoSmithKline · 16 drugs in this class
2. Seqirus · 5 drugs in this class
3. Sanofi Pasteur, a Sanofi Company · 5 drugs in this class
4. Green Cross Corporation · 4 drugs in this class
5. Novartis · 2 drugs in this class
6. SK Chemicals Co., Ltd. · 2 drugs in this class
7. Sanofi · 2 drugs in this class
8. Hospital Israelita Albert Einstein · 2 drugs in this class
9. McGill University Health Centre/Research Institute of the McGill University Health Centre · 2 drugs in this class
10. Il-Yang Pharm. Co., Ltd. · 2 drugs in this class